Lipoprotein(a) as a cardiovascular risk factor: current status. - Archive ouverte HAL Access content directly
Journal Articles European Heart Journal Year : 2010

Lipoprotein(a) as a cardiovascular risk factor: current status.

(1) , (2) , (3) , (4) , (5) , (6) , (7) , (8) , (9) , (10) , (11) , (12) , (13) , (2) , (14) , (15) , (16) , (17) , (18)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
Marja-Riitta Taskinen
  • Function : Author

Abstract

AIMS: The aims of the study were, first, to critically evaluate lipoprotein(a) [Lp(a)] as a cardiovascular risk factor and, second, to advise on screening for elevated plasma Lp(a), on desirable levels, and on therapeutic strategies. METHODS AND RESULTS: The robust and specific association between elevated Lp(a) levels and increased cardiovascular disease (CVD)/coronary heart disease (CHD) risk, together with recent genetic findings, indicates that elevated Lp(a), like elevated LDL-cholesterol, is causally related to premature CVD/CHD. The association is continuous without a threshold or dependence on LDL- or non-HDL-cholesterol levels. Mechanistically, elevated Lp(a) levels may either induce a prothrombotic/anti-fibrinolytic effect as apolipoprotein(a) resembles both plasminogen and plasmin but has no fibrinolytic activity, or may accelerate atherosclerosis because, like LDL, the Lp(a) particle is cholesterol-rich, or both. We advise that Lp(a) be measured once, using an isoform-insensitive assay, in subjects at intermediate or high CVD/CHD risk with premature CVD, familial hypercholesterolaemia, a family history of premature CVD and/or elevated Lp(a), recurrent CVD despite statin treatment, ≥3% 10-year risk of fatal CVD according to European guidelines, and/or ≥10% 10-year risk of fatal + non-fatal CHD according to US guidelines. As a secondary priority after LDL-cholesterol reduction, we recommend a desirable level for Lp(a) <80th percentile (less than ∼50 mg/dL). Treatment should primarily be niacin 1-3 g/day, as a meta-analysis of randomized, controlled intervention trials demonstrates reduced CVD by niacin treatment. In extreme cases, LDL-apheresis is efficacious in removing Lp(a). CONCLUSION: We recommend screening for elevated Lp(a) in those at intermediate or high CVD/CHD risk, a desirable level <50 mg/dL as a function of global cardiovascular risk, and use of niacin for Lp(a) and CVD/CHD risk reduction.
Fichier principal
Vignette du fichier
Lipoprotein_a_as.2010_31_2844-2853.pdf (426.19 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Loading...

Dates and versions

inserm-00578888 , version 1 (24-03-2011)

Identifiers

Cite

Børge G. Nordestgaard, M John Chapman, Kausik Ray, Jan Borén, Felicita Andreotti, et al.. Lipoprotein(a) as a cardiovascular risk factor: current status.. European Heart Journal, 2010, 31 (23), pp.2844-53. ⟨10.1093/eurheartj/ehq386⟩. ⟨inserm-00578888⟩
169 View
559 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More